                         SEQUENCE LISTING

<110>  The Regents of the University of California
 
<120>  Netrin-1 Compounds and Compositions Thereof for Treating 
       Pulmonary Hypertension

<130>  034044.195P1

<160>  17    

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is Ala, Asn, Cys, Ser, or Thr, and wherein when X1 is Cys, it
       is linked to either the cysteine residue at the fourth amino acid
       position via a disulfide bond or an ethylene oxide

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is present or absent, and if present, Xaa is Ala, Asp, Ile, 
       Leu, Met, Phe, Pro, Trp, or Val, and wherein this Xaa is present 
       where the Xaa in the third amino acid position is absent

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is present or absent, and if present, Xaa is Asn, Arg, Asp, 
       Cys, Gln, Glu, Gly, Ser, Thr, or Tyr, and wherein this Xaa is 
       present where the Xaa in the second amino acid position is absent

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Arg, His, or Lys

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is Arg, Asp, Glu, His, Lys, Phe, Trp, or Tyr

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is Asn, Cys, Gln, Gly, Ser, Thr, Tyr, or Val

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is present or absent, and if present, Xaa is Asn, Gly, His, 
       Ile, Thr, or Val

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is present or absent, and if present, Xaa is Ala, Asn, Ile, 
       Leu, Met, Phe, Pro, Thr, Trp, or Val

<400>  1

Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Thr Xaa Gly 
1               5                   10      


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein diethylene glycol (mini-PEG) is linked thereto

<400>  2

Cys Asp Cys Arg His Asn Thr Ala Gly 
1               5                   


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein diethylene glycol (mini-PEG) is linked thereto

<400>  3

Cys Leu Asn Cys Arg His Asn Thr Ala Gly 
1               5                   10  


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Wherein diethylene glycol (mini-PEG) is linked thereto

<400>  4

Cys Pro Cys Lys Asp Gly Val Thr Ile Gly Ile Thr 
1               5                   10          


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  5

Ser Asp Cys Arg His Asn Thr Ala Gly 
1               5                   


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  6

Thr Asp Cys Arg His Asn Thr Ala Gly 
1               5                   


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence


<220>
<221>  DISULFID
<222>  (1)..(3)

<400>  7

Cys Asp Cys Arg His Asn Thr Ala Gly 
1               5                   


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  D-amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  D-amino acid residue

<400>  8

Cys Asp Cys Arg His Asn Thr Ala Gly 
1               5                   


<210>  9
<211>  604
<212>  PRT
<213>  Homo sapiens

<400>  9

Met Met Arg Ala Val Trp Glu Ala Leu Ala Ala Leu Ala Ala Val Ala 
1               5                   10                  15      


Cys Leu Val Gly Ala Val Arg Gly Gly Pro Gly Leu Ser Met Phe Ala 
            20                  25                  30          


Gly Gln Ala Ala Gln Pro Asp Pro Cys Ser Asp Glu Asn Gly His Pro 
        35                  40                  45              


Arg Arg Cys Ile Pro Asp Phe Val Asn Ala Ala Phe Gly Lys Asp Val 
    50                  55                  60                  


Arg Val Ser Ser Thr Cys Gly Arg Pro Pro Ala Arg Tyr Cys Val Val 
65                  70                  75                  80  


Ser Glu Arg Gly Glu Glu Arg Leu Arg Ser Cys His Leu Cys Asn Ala 
                85                  90                  95      


Ser Asp Pro Lys Lys Ala His Pro Pro Ala Phe Leu Thr Asp Leu Asn 
            100                 105                 110         


Asn Pro His Asn Leu Thr Cys Trp Gln Ser Glu Asn Tyr Leu Gln Phe 
        115                 120                 125             


Pro His Asn Val Thr Leu Thr Leu Ser Leu Gly Lys Lys Phe Glu Val 
    130                 135                 140                 


Thr Tyr Val Ser Leu Gln Phe Cys Ser Pro Arg Pro Glu Ser Met Ala 
145                 150                 155                 160 


Ile Tyr Lys Ser Met Asp Tyr Gly Arg Thr Trp Val Pro Phe Gln Phe 
                165                 170                 175     


Tyr Ser Thr Gln Cys Arg Lys Met Tyr Asn Arg Pro His Arg Ala Pro 
            180                 185                 190         


Ile Thr Lys Gln Asn Glu Gln Glu Ala Val Cys Thr Asp Ser His Thr 
        195                 200                 205             


Asp Met Arg Pro Leu Ser Gly Gly Leu Ile Ala Phe Ser Thr Leu Asp 
    210                 215                 220                 


Gly Arg Pro Ser Ala His Asp Phe Asp Asn Ser Pro Val Leu Gln Asp 
225                 230                 235                 240 


Trp Val Thr Ala Thr Asp Ile Arg Val Ala Phe Ser Arg Leu His Thr 
                245                 250                 255     


Phe Gly Asp Glu Asn Glu Asp Asp Ser Glu Leu Ala Arg Asp Ser Tyr 
            260                 265                 270         


Phe Tyr Ala Val Ser Asp Leu Gln Val Gly Gly Arg Cys Lys Cys Asn 
        275                 280                 285             


Gly His Ala Ala Arg Cys Val Arg Asp Arg Asp Asp Ser Leu Val Cys 
    290                 295                 300                 


Asp Cys Arg His Asn Thr Ala Gly Pro Glu Cys Asp Arg Cys Lys Pro 
305                 310                 315                 320 


Phe His Tyr Asp Arg Pro Trp Gln Arg Ala Thr Ala Arg Glu Ala Asn 
                325                 330                 335     


Glu Cys Val Ala Cys Asn Cys Asn Leu His Ala Arg Arg Cys Arg Phe 
            340                 345                 350         


Asn Met Glu Leu Tyr Lys Leu Ser Gly Arg Lys Ser Gly Gly Val Cys 
        355                 360                 365             


Leu Asn Cys Arg His Asn Thr Ala Gly Arg His Cys His Tyr Cys Lys 
    370                 375                 380                 


Glu Gly Tyr Tyr Arg Asp Met Gly Lys Pro Ile Thr His Arg Lys Ala 
385                 390                 395                 400 


Cys Lys Ala Cys Asp Cys His Pro Val Gly Ala Ala Gly Lys Thr Cys 
                405                 410                 415     


Asn Gln Thr Thr Gly Gln Cys Pro Cys Lys Asp Gly Val Thr Gly Ile 
            420                 425                 430         


Thr Cys Asn Arg Cys Ala Lys Gly Tyr Gln Gln Ser Arg Ser Pro Ile 
        435                 440                 445             


Ala Pro Cys Ile Lys Ile Pro Val Ala Pro Pro Thr Thr Ala Ala Ser 
    450                 455                 460                 


Ser Val Glu Glu Pro Glu Asp Cys Asp Ser Tyr Cys Lys Ala Ser Lys 
465                 470                 475                 480 


Gly Lys Leu Lys Ile Asn Met Lys Lys Tyr Cys Lys Lys Asp Tyr Ala 
                485                 490                 495     


Val Gln Ile His Ile Leu Lys Ala Asp Lys Ala Gly Asp Trp Trp Lys 
            500                 505                 510         


Phe Thr Val Asn Ile Ile Ser Val Tyr Lys Gln Gly Thr Ser Arg Ile 
        515                 520                 525             


Arg Arg Gly Asp Gln Ser Leu Trp Ile Arg Ser Arg Asp Ile Ala Cys 
    530                 535                 540                 


Lys Cys Pro Lys Ile Lys Pro Leu Lys Lys Tyr Leu Leu Leu Gly Asn 
545                 550                 555                 560 


Ala Glu Asp Ser Pro Asp Gln Ser Gly Ile Val Ala Asp Lys Ser Ser 
                565                 570                 575     


Leu Val Ile Gln Trp Arg Asp Thr Trp Ala Arg Arg Leu Arg Lys Phe 
            580                 585                 590         


Gln Gln Arg Glu Lys Lys Gly Lys Cys Lys Lys Ala 
        595                 600                 


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  10

Cys Asp Cys Arg His Asn Thr Ala Gly 
1               5                   


<210>  11
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  11

Cys Leu Asn Cys Arg His Asn Thr Ala Gly 
1               5                   10  


<210>  12
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  12

Cys Pro Cys Lys Asp Gly Val Thr Gly Ile Thr 
1               5                   10      


<210>  13
<211>  54
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  13

Cys Lys Cys Asn Gly His Ala Ala Arg Cys Val Arg Asp Arg Asp Asp 
1               5                   10                  15      


Ser Leu Val Cys Asp Cys Arg His Asn Thr Ala Gly Pro Glu Cys Asp 
            20                  25                  30          


Arg Cys Lys Pro Phe His Tyr Asp Arg Pro Trp Gln Arg Ala Thr Ala 
        35                  40                  45              


Arg Glu Ala Asn Glu Cys 
    50                  


<210>  14
<211>  61
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  14

Cys Asn Cys Asn Leu His Ala Arg Arg Cys Arg Phe Asn Met Glu Leu 
1               5                   10                  15      


Tyr Lys Leu Ser Gly Arg Lys Ser Gly Gly Val Cys Leu Asn Cys Arg 
            20                  25                  30          


His Asn Thr Ala Gly Arg His Cys His Tyr Cys Lys Glu Gly Tyr Tyr 
        35                  40                  45              


Arg Asp Met Gly Lys Pro Ile Thr His Arg Lys Ala Cys 
    50                  55                  60      


<210>  15
<211>  48
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  15

Cys Asp Cys His Pro Val Gly Ala Ala Gly Lys Thr Cys Asn Gln Thr 
1               5                   10                  15      


Thr Gly Gln Cys Pro Cys Lys Asp Gly Val Thr Gly Ile Thr Cys Asn 
            20                  25                  30          


Arg Cys Ala Lys Gly Tyr Gln Gln Ser Arg Ser Pro Ile Ala Pro Cys 
        35                  40                  45              


<210>  16
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  16

Asn Leu His Ala Arg Arg Cys Arg Phe Asn Met Glu Leu Tyr Lys Leu 
1               5                   10                  15      


Ser Gly Arg Lys Ser Gly Gly Val Cys Leu Asn Cys Arg His Asn Thr 
            20                  25                  30          


Ala Gly Arg His 
        35      


<210>  17
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide based on human Netrin-1 sequence

<400>  17

His Pro Val Gly Ala Ala Gly Lys Thr Cys Asn Gln Thr Thr Gly Gln 
1               5                   10                  15      


Cys Pro Cys Lys Asp Gly Val Thr Gly Ile Thr 
            20                  25          


